ANDA 40013, held by Hospira. Lidocaine Hydrochloride.
As of Nov 16, 2026, ANDA 40013 (Lidocaine Hydrochloride), held by Hospira, was first approved by FDA on Jun 23, 1995, with 4 approved supplements and 0 published complete response letters.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Jun 23, 1995 | Original application | Approved | None posted |
| Product | Active ingredient | Marketing |
|---|---|---|
| Lidocaine Hydrochloride1% ยท injectable;injection | Lidocaine Hydrochloride | Discontinued |
| Jan 2, 2002 | Supplement 4Labeling | Approved | None posted |
| Feb 14, 2001 | Supplement 3Manufacturing | Approved | None posted |
| May 7, 1996 | Supplement 2Manufacturing | Approved | None posted |
| Apr 23, 1996 | Supplement 1Manufacturing | Approved | None posted |
| Jun 23, 1995 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters